ASX:NEU

Stock Analysis Report

Executive Summary

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain injury.

Snowflake

Fundamentals

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Neuren Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

12.0%

NEU

0.05%

AU Pharmaceuticals

1.3%

AU Market


1 Year Return

107.1%

NEU

-32.9%

AU Pharmaceuticals

9.9%

AU Market

Return vs Industry: NEU exceeded the Australian Pharmaceuticals industry which returned -32.9% over the past year.

Return vs Market: NEU exceeded the Australian Market which returned 9.9% over the past year.


Share holder returns

NEUIndustryMarket
7 Day12.0%0.05%1.3%
30 Day15.3%2.1%-0.7%
90 Day62.9%-5.3%-0.4%
1 Year107.1%107.1%-32.8%-32.9%16.3%9.9%
3 Year142.7%142.7%-47.3%-47.8%35.8%17.6%
5 Year37.1%37.1%-19.1%-26.7%51.9%17.8%

Price Volatility Vs. Market

How volatile is Neuren Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Neuren Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

13.91x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Undervalued: Insufficient data to calculate NEU's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate NEU's fair value to establish if it is undervalued.


Price Based on Earnings

PE vs Industry: NEU is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: NEU is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price Based on Expected Growth

Low PEG Ratio: Insufficient data to calculate NEU's PEG Ratio to determine if it is good value.


Price Based on Value of Assets

PB vs Industry: NEU is overvalued based on its PB Ratio (13.9x) compared to the AU Pharmaceuticals industry average (3.3x).


Next Steps

  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is Neuren Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

40.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: NEU is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NEU is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NEU is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NEU's revenue is expected to decline over the next 3 years (-35.9% per year).

High Growth Revenue: NEU's revenue is forecast to decline over the next 3 years (-35.9%).


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: NEU is forecast to be unprofitable in 3 years.


Next Steps

Past Performance

How has Neuren Pharmaceuticals performed over the past 5 years?

42.7%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: NEU is unprofitable, but has reduced losses over the past 5 years at a rate of 42.7% per year.

Accelerating Growth: Unable to compare NEU's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: NEU is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (7%).


Return on Equity

High ROE: NEU has a negative Return on Equity (-4.27%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: NEU is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: NEU is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Neuren Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: NEU's short term assets (A$18.1M) exceeds its short term liabilities (A$1.3M)

Long Term Liabilities: NEU has no long term liabilities


Debt to Equity History and Analysis

Debt Level: NEU is debt free.

Reducing Debt: NEU has not had any debt for past 5 years.


Balance Sheet

Inventory Level: NEU has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if NEU's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable NEU has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: NEU is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 92.5% per year.


Next Steps

Dividend

What is Neuren Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.5%markettop25%5.6%industryaverage1.4%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate NEU's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate NEU's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if NEU's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if NEU's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of NEU's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

What is the CEO of Neuren Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

1.3yrs

Average board tenure


CEO

Neuren Pharmaceuticals has no CEO, or we have no data on them.


Board Age and Tenure

1.3yrs

Average Tenure

Experienced Board: NEU's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

SellAU$21,07330 Dec 18
Lanstead Capital Limited Partnership
EntityCompany
Shares7,645
Max PriceAU$3.27
SellAU$5,829,91230 Dec 18
Lanstead Capital Limited Partnership
EntityCompany
Shares4,164,223
Max PriceAU$1.40

Ownership Breakdown


Management Team

  • Larry Glass

    Chief Science Officer

    • Tenure: 15.8yrs
  • Jon Pilcher

    CFO & Company Secretary

    • Tenure: 6.2yrs
  • Richard Treagus

    Executive Chairman

    • Tenure: 6.8yrs

Board Members

  • Dianne Angus (59yo)

    Independent Non-Executive Director

    • Tenure: 1.3yrs
  • Trevor Scott

    Independent Non-Executive Director

    • Tenure: 17.6yrs
  • Jenny Harry

    Independent Non-Executive Director

    • Tenure: 1.3yrs
  • Richard Treagus

    Executive Chairman

    • Tenure: 6.8yrs
  • Patrick Davies

    Independent Non-Executive Director

    • Tenure: 1.3yrs

Company Information

Neuren Pharmaceuticals Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Neuren Pharmaceuticals Limited
  • Ticker: NEU
  • Exchange: ASX
  • Founded: 1993
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$233.392m
  • Shares outstanding: 100.17m
  • Website: https://www.neurenpharma.com

Number of Employees


Location

  • Neuren Pharmaceuticals Limited
  • 697 Burke Road
  • Suite 201
  • Camberwell
  • Victoria
  • 3124
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
NEUASX (Australian Securities Exchange)YesOrdinary SharesAUAUDFeb 2005
NURP.FOTCPK (Pink Sheets LLC)YesOrdinary SharesUSUSDFeb 2005
NEUCHIA (Chi-X Australia)YesOrdinary SharesAUAUDFeb 2005
NEUCHIA (Chi-X Australia)YesOrdinary SharesAUAUDFeb 2005

Biography

Neuren Pharmaceuticals Limited, a biopharmaceutical company, engages in the development of drugs for the treatment of chronic neurodevelopmental and neurodegenerative disorders, and acute traumatic brain i ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 10:30
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)